RT Journal Article
T1 POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1
A1 Martínez‐López, Angélica
A1 García Casas, Ana
A1 Infante, Guiomar
A1 González‐Fernández, Mónica
A1 Salvador, Nélida
A1 Lorente, Mar
A1 Mendiburu-Eliçabe Garganta, Marina
A1 Gonzalez‐Moreno, Santiago
A1 Villarejo‐Campos, Pedro
A1 Malliri, Angeliki
A1 Lorente Pérez, María Del Mar
A1 Velasco Díez, Guillermo
A1 Castillo Lluva, Sonia
AB TThe small GTPase Rac1 (Ras-related C3 botulinum toxin substrate 1) has been implicated in cancer progression and in the poor prognosis of various types of tumors. Rac1 SUMOylation occurs during epithelial-mesenchymal transition (EMT), and it is required for tumor cell migration and invasion. Here we identify POTEE (POTE Ankyrin domain family member E) as a novel Rac1-SUMO1 effector involved in breast cancer malignancy that controls invadopodium formation through the activation of Rac1-SUMO1. POTEE activates Rac1 in the invadopodium by recruiting TRIO-GEF (triple functional domain protein), and it induces tumor cell proliferation and metastasis in vitro and in vivo. We found that the co-localization of POTEE with Rac1 is correlated with more aggressive breast cancer subtypes. Given its role in tumor dissemination, the leading cause of cancer-related deaths, POTEE could represent a potential therapeutic target for these types of cancer.
SN 1574-7891
YR 2023
FD 2023-12-27
LK https://hdl.handle.net/20.500.14352/100434
UL https://hdl.handle.net/20.500.14352/100434
LA eng
NO Martínez‐López A, García‐Casas A, Infante G, González‐Fernández M, Salvador N, Lorente M, et al. POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1. Molecular Oncology 2024;18:620–40. https://doi.org/10.1002/1878-0261.13568.
NO Cancer Research UK
NO Ministerio de Economía, Comercio y Empresa (España)
NO Federación Española de Enfermedades Raras
DS Docta Complutense
RD 8 abr 2025